PATHOPHYSIOLOGICAL SUBSTANTIATION OF THE USE OF A NEW  DRUG BASED ON G. LUCIDUM AND ALKHADIA IN THE TREATMENT  OF CORONAVIRUS INFECTION CAUSED BY SARS COV-2

Pulat M. Abilov1 , Bakhtiyor U. Iriskulov2 , Zukhra N. Boboeva3

dc.contributor.author	Pulat M. Abilov1 , Bakhtiyor U. Iriskulov2 , Zukhra N. Boboeva3
dc.date.accessioned	2023-04-25T13:00:00Z
dc.date.available	2023-04-25T13:00:00Z
dc.date.issued	2022
dc.identifier.issn	2186-1326
dc.identifier.uri	http://repository.tma.uz/xmlui/handle/1/7192
dc.description.abstract	The current outbreak of coronavirus disease (COVID-19) is a global emergency as its rapid spread and high mortality rate have caused severe disruption. The number of people infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, is rapidly increasing worldwide. Patients with COVID-19 may develop pneumonia, severe symptoms of acute respiratory distress syndrome (ARDS) and multiple organ failure	en_US
dc.relation.ispartofseries	№3;
dc.subject	coronavirus infection, pathogenesis, acute respiratory syndrome, G. lucidum, Alkhadaya	en_US
dc.title	PATHOPHYSIOLOGICAL SUBSTANTIATION OF THE USE OF A NEW DRUG BASED ON G. LUCIDUM AND ALKHADIA IN THE TREATMENT OF CORONAVIRUS INFECTION CAUSED BY SARS COV-2	en_US
dc.type	Article	en_US